Study of Cesium-131 Brachytherapy published in Journal of Neuro-Oncology- IsoRay
IsoRay has announced a peer-reviewed publication of the results of a retrospective study on the cost effectiveness of Cesium-131 Brachytherapy in combination with surgical resection for metastatic brain tumors. The study concluded that surgical resection plus Cesium-131 (S + Cs-131) is a more cost effective alternative to surgical resection and stereotactic radiosurgery (S + SRS), with direct hospital costs of treatment of $19,271 for S + Cs-131 and $44,219 for S + SRS. Median survival was greater for S + Cs-131 and resulted in a greater quality adjusted life years (QALY). Relative to S + Cs-131, S + SRS resulted in a negative incremental cost-effectiveness ratio (ICER) as it was more expensive yet provided a lower QALY.
Therefore, from a resource allocation perspective, this study concluded that S + Cs-131 for brain metastases is the more cost-effective treatment option while providing a better quality of life. The study was published online on January 2, 2016, in the Journal of Neuro-Oncology.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins